Print
13 March 2018
GMP News
The Russian government adopted the action plan (roadmap) for the Development of Biotechnology and Genetic Engineering in 2018 – 2020.
The plan aims at developing domestic demand, manufacturing and exports of biotech products, and building institutional environment in order to modernize the technology base of the industry through mass introduction of biotech methods and products.
It provides for further expansion of production potential and cooperation in the area of biomedicine and biopharmaceuticals, agricultural and industrial biotechnology, bioenergetics, forest and environmental biotechnology, and genetic engineering.
By 2020, 2 common use production centers licensed for manufacturing biomedical cell products will be established to conduct R&D and pre-clinical studies of biomedical cell products.
The number of medical institutions accredited for clinical trials of biomedical cell products will be increased from 5 to 50.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.